Safety of Toll-like receptor 9 agonists: A systematic review and meta-analysis

Immunopharmacology and Immunotoxicology

Volumn 36, Issue 4, 2014, Pages 251-260

  Qin, Mei ^a   Li, Yong ^b   Yang, Xu ^a   Wu, Hongquan ^c  

^a First People's Hospital of Guiyang   (China)

^b Transfusion Section of Guiyang Maternal and Child Health Hospital   (China)

^c Department of Pediatrics   (China)

Author keywords

Adverse event; Flu like symptom; Immunosuppressive agent; Systematic review; Toll like receptor 9 agonist

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TLR9 PROTEIN, HUMAN;

ANEMIA; AUTOIMMUNE DISEASE; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL (TOPIC); DEATH; DIZZINESS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ERYTHEMA; FEVER; FLU LIKE SYNDROME; HEADACHE; HIGH RISK PATIENT; HUMAN; INJECTION SITE EDEMA; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; META ANALYSIS; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SWELLING; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; WEAKNESS; YAWS; AGONISTS; CLINICAL TRIAL (TOPIC); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; TOLL-LIKE RECEPTOR 9;

EID: 84905503992     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2013.861481     Document Type: Review

References (28)

1. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009;21:317-337.
2. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19:3-10.
3. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from Toll-like receptors. Science 2004;304:1014-1018.
4. Gosu V, Basith S, Kwon OP, Choi S. Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling. Molecules 2012;17:13503-13529.
5. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006;117:979-987.
6. Coopera CL, Davisb HL, Angela JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviraltreated HIV-infected adults. AIDS 2005;19:1473-1479.
7. Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41: 1305-1312.
8. Thompson JA, Kuzel T, Drucker BJ, et al. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009;7:E58-E65.
9. Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008; 31:520-527.
10. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-1573.
11. Kim YH, Gratzinger D, Harrison C, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012;119: 355-363.
12. Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010;28:4324-3432.
13. Kim YH, Girardi M, Duvic M, et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010;63:975-983.
14. Yamada K, Nakao M, Fukuyama C, et al. Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Sci 2010;101:188-195.
15. Friedberg JW, Kelly JL, Neuberg D, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009;146:282-291.
16. Leonard JP, Link BK, Emmanouilides C, et al. Phase I trial of Tolllike receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkins lymphoma. Clin Cancer Res 2007;13:6168-6174.
17. Pashenkov M, Goëss G, Wagner C, et al. Phase II trial of a Toll- Like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006;24:5716-5724.
18. Hirsh V, Paz-Ares L, Boyer M, et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-smallcell lung cancer. J Clin Oncol 2011;29:2667-2674.
19. Manegold C, van Zandwijk N, Szczesna A, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung Cancer. Ann Oncol 2012;23:72-77.
20. Sgaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a Toll-like receptor 9 agonist adjuvant: a randomized, controlled Trial. Clin Infect Dis 2010;51:42-50.
21. Manegold C, Gravenor D, Woytowitz D, et al. Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3979-3986.
22. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004;24:693-701.
23. Weber JS, Zarour H, Redman B, et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 2009;115:3944-3954.
24. McHutchison JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10 101 in patients with chronic hepatitis C virus. Hepatology 2007;46:1341-1349.
25. Vicari AP, Schmalbach T, Lekstrom-Himes J, et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10 101 (ACTILON), an investigational synthetic Toll-like receptor 9 agonist. Antivir Ther 2007;12:741-751.
26. Krieg AM, Efler SM, Wittpoth M, et al. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004;27:460-471.
27. Beeh KM, Kanniess F, Wagner F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013;131:866-874.
28. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161-167.